Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Neuroactive steroid

or Research material

Use the filters below to narrow your results.

None (2)

Other values:

None (131) · (none, never marketed) (1) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · O-DSMT (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1) · Zulresso (1) · Zurzuvae (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Irreversible non-selective MAO inhibitor (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

None (149) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · Postpartum depression (PPD) in adults (1) · Postpartum depression (PPD) in adults (FDA-approved 2023) (1)

None (149) · 25 mg (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h (1)

None (149) · 100 mg/20 mL vial, single-use (1) · 20 mg, 25 mg, 30 mg capsules (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (149) · 200 mg/d (1) · 50 mg/d × 14 d (1) · N/A (never approved) (1) · Single 60-hour course (1)

None (148) · intranasal; rectal and IV reported. (1) · Intravenous (continuous infusion in a REMS-certified facility) (1) · Oral (4) · sublingual (1)

None (148) · Antidepressant effect within hours of infusion start; sustained at 30 days (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Day 3 of dosing in trials; sustained through day 45 (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (148) · 14-day course; effect persists after discontinuation in trials (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · Chronic daily dosing (1) · Long (1) · Single infusion course (1)

None (148) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~12 hours (1) · ~16-23 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~9 hours (terminal) (1)

None (148) · 100% (IV) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Adequate (food-dependent, must take with fatty meal) (1) · Not formally characterized in humans. (1) · ~50% (highly variable) (1)

None (148) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Medicine is structurally identical to endogenous allopregnanolone; pregnancy considerations relate to breastfeeding during/after infusion. Limited data; brief interruption of breastfeeding considered (1)

None (149) · Rx, Schedule IV (US) (1) · Rx-only (1) · Rx-only in US (1) · Rx; REMS program required (excessive sedation/loss of consciousness during infusion) (1)

1

2

3

4

5

A

B

C

D

E

F

G

H

I

J

L

M

N

O

P

R

S

T

U

Z